Insys Therapeutics (INSY) 10-Q/A 7 Apr 17 2016 Q1 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May 01, 2016
Document Information [Line Items]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	We are filing this Amendment No. 1 to our Quarterly Report on Form 10-Q (the “Amended Form 10-Q”) to restate and amend our previously issued, unaudited condensed consolidated financial statements and related financial information as of March 31, 2016 and 2015 and for the quarters ended March 31, 2016 and 2015, which was originally filed with the U.S. Securities and Exchange Commission on May 5, 2016 (the “Original Form 10-Q”). The restatement is the result of a misapplication of the accounting guidance in Accounting Standards Codification (“ASC”) No. 605, “Revenue Recognition” related to accounting for rebate obligations on government payer and managed care contracts. We also reversed an out-of-period adjustment related to a stock option modification previously recorded during the three months ended March 31, 2016 that related to the fourth quarter of 2015. This resulted in a decrease in operating expenses of $1,500,000 for the three months ended March 31, 2016 and a corresponding increase in operating expenses during the three months ended December 31, 2015. We assessed the impact of these errors on our prior unaudited condensed consolidated financial statements and concluded that the impact was material to these unaudited condensed consolidated financial statements. In order to correctly present net revenue and operating expenses in the appropriate periods during 2016 and 2015, we have restated the unaudited condensed consolidated financial information included herein.
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	INSY
Entity Registrant Name	Insys Therapeutics, Inc.
Entity Central Index Key	1,516,479
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding (in shares)		71,546,491

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Current Assets:
Cash and cash equivalents	$ 73,820	$ 79,515	$ 70,074
Short-term investments	89,808	79,576	31,386
Accounts receivable, net of allowances of $4,781, $8,367 and 8,333 at March 31, 2016, December 31, 2015 and March 31, 2015, respectively	20,663	47,272	31,617
Inventories, net	32,241	41,715	35,236
Prepaid expenses and other current assets	4,077	3,973	5,982
Total current assets	220,609	252,051	174,295
Property and equipment, net	39,618	38,382	33,846
Long-term investments	36,443	43,219	22,891
Deferred income tax assets,net	18,192	17,607	13,635
Other assets	11,165	26	3,518
Total assets	326,027	351,285	248,185
Current Liabilities:
Accounts payable and accrued expenses	24,590	35,611	28,434
Accrued compensation	7,239	10,225	7,009
Accrued sales allowances	29,742	35,033	21,326
Accrued litigation award and settlements	9,567	9,567	8,144
Total current liabilities	71,138	90,436	64,913
Uncertain income tax position	7,390	8,544	3,736
Total liabilities	78,528	98,980	68,649
Stockholders' Equity:
Preferred stock (par value $0.01 per share; 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2016, December 31, 2015 and March 31, 2015, respectively)
Common stock (par value $0.01 per share; 100,000,000 shares authorized; 71,532,258, 71,907,858 and 71,337,170 shares issued and outstanding as of March 31, 2016 , December 31, 2015 and March 31, 2015, respectively)	715	719	713
Additional paid in capital	239,427	246,685	225,952
Unrealized gain (loss) on available-for-sale securities	14	(152)	4
Notes receivable from stockholders	(21)	(21)	(21)
Retained earnings (accumulated deficit)	7,364	5,074	(47,112)
Total stockholders' equity	247,499	252,305	179,536
Total liabilities and stockholders' equity	$ 326,027	$ 351,285	$ 248,185

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Accounts receivable, allowance for doubtful accounts	$ 4,781	$ 8,367	$ 8,333
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0	0
Preferred stock, shares outstanding (in shares)	0	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000	100,000,000
Common stock, shares issued (in shares)	71,532,258	71,907,858	71,337,170
Common stock, shares outstanding (in shares)	71,532,258	71,907,858	71,337,170

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net revenue	$ 60,421	$ 67,692
Cost of revenue	4,638	6,375
Gross profit	55,783	61,317
Operating expenses:
Sales and marketing	19,800	20,916
Research and development	19,035	10,602
General and administrative	14,698	13,246
Charges related to litigation award and settlements		8,000
Total operating expenses	53,533	52,764
Operating income	2,250	8,553
Other income:
Interest income	225	125
Other income, net	49
Total other income	274	125
Income before income taxes	2,524	8,678
Less: income tax expense	234	2,811
Net income	2,290	5,867
Unrealized gain on available-for-sale securities	166	28
Total comprehensive income	$ 2,456	$ 5,895
Net income per common share:
Basic (in dollars per share)	$ 0.03	$ 0.08
Diluted (in dollars per share)	$ 0.03	$ 0.08
Weighted average common shares outstanding
Basic (in shares)	71,592,089	70,916,828
Diluted (in shares)	74,462,878	74,918,318

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Receivables from Stockholder [Member]	Retained Earnings (Accumulated Deficit) [Member]
Balance (in shares) at Dec. 31, 2014		70,702,688
Balance at Dec. 31, 2014	$ 163,190	$ 707	$ 215,507	$ (24)	$ (21)	$ (52,979)
Exercise of stock options (in shares)		634,482
Exercise of stock options	3,130	$ 6	3,124
Excess tax benefits on stock options and awards	3,601		3,601
Stock based compensation - stock options and awards	3,720		3,720
Unrealized gain on available-for-sale securities	28			28
Net income	5,867					5,867
Balance (in shares) at Mar. 31, 2015		71,337,170
Balance at Mar. 31, 2015	179,536	$ 713	225,952	4	(21)	(47,112)
Balance (in shares) at Dec. 31, 2015		71,907,858
Balance at Dec. 31, 2015	$ 252,305	$ 719	246,685	(152)	(21)	5,074
Exercise of stock options (in shares)	265,325	265,325
Exercise of stock options	$ 1,310	$ 2	1,308
Excess tax benefits on stock options and awards	653		653
Stock based compensation - stock options and awards	4,126		4,126
Unrealized gain on available-for-sale securities	166			166
Repurchase of common stock (in shares)		(640,925)
Repurchase of common stock	(13,351)	$ (6)	(13,345)
Net income	2,290					2,290
Balance (in shares) at Mar. 31, 2016		71,532,258
Balance at Mar. 31, 2016	$ 247,499	$ 715	$ 239,427	$ 14	$ (21)	$ 7,364

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income	$ 2,290	$ 5,867
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,527	1,175
Stock-based compensation	4,126	3,720
Deferred income tax benefit	(585)	(942)
Loss on disposal of assets		41
Excess tax benefits on stock options and awards	(653)	(3,601)
Amortization of investment discount	569	194
Changes in operating assets and liabilities:
Accounts receivable	26,609	(8,115)
Inventories	(1,665)	(1,079)
Prepaid expenses and other current assets	(104)	(214)
Accounts payable, accrued expenses and other current liabilities	(19,799)	11,806
Accrued litigation award and settlements		8,000
Net cash provided by operating activities	12,315	16,852
Cash flows from investing activities:
Purchase of investments	(22,574)	(10,469)
Proceeds from sales of investments	2,108
Proceeds from maturities of investments	16,607	4,045
Purchases of property and equipment	(2,763)	(5,191)
Net cash used in investing activities	(6,622)	(11,615)
Cash flows from financing activities:
Excess tax benefits on stock options and awards	653	3,601
Proceeds from exercise of stock options	1,310	3,130
Repurchase of common stock	(13,351)
Net cash (used in) provided by financing activities	(11,388)	6,731
Change in cash and cash equivalents	(5,695)	11,968
Cash and cash equivalents, beginning of period	79,515	58,106
Cash and cash equivalents, end of period	73,820	70,074
Supplemental cash flow disclosures:
Cash paid for interest expense	0	0
Cash paid for income taxes	$ 0	$ 0

Organization, Consolidation and

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Nature of Business and Basis of Presentation Insys Therapeutics, Inc., which was incorporated in Delaware in June 1990, and our subsidiaries (collectively, “we,” “us,” and “our”) maintain headquarters in Chandler, Arizona. We are a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have one marketed product: Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients. The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles, pursuant to rules and regulations of the SEC. Certain information and footnote disclosures have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements include normal recurring adjustments that are necessary for a fair presentation of the results for the interim periods presented. These condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2015 included in our Annual Report on Form 10-K. The results of operations for the three months ended March 31, 2016 and 2015 are not necessarily indicative of results to be expected for the full fiscal year or any other periods. The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make a number of estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to revenue recognition (which is affected by prescriptions dispensed, wholesaler discounts, patient discount programs, rebates and chargebacks), inventories, stock-based compensation expense, and deferred tax valuation allowances. We base our estimates on historical experience and on various other assumptions that are believed by management to be reasonable under the circumstances. Actual results may materially differ from these estimates. On May 5, 2015, our Board of Directors approved a two-for-one stock split of our common stock that was effected through a stock dividend. The record date for the stock split was the close of business on May 26, 2015, with share distribution occurring on June 8, 2015. As a result of the dividend, shareholders received one additional share of Insys Therapeutics, Inc. common stock, par value $0.01, for each one share they held as of the record date. All share and per share amounts have been retroactively restated for the effects of this stock split. Certain prior period amounts have been reclassified to conform with current period presentation. All significant intercompany balances and transactions have been eliminated in the accompanying unaudited condensed consolidated financial statements. Restatement of Financial Statements We are filing this Amendment No. 1 to our Quarterly Report on Form 10-Q (the “Amended Form 10-Q”) to restate and amend our previously issued, unaudited condensed consolidated financial statements and related financial information as of March 31, 2016 and 2015 and for the quarters ended March 31, 2016 and 2015, which was originally filed with the U.S. Securities and Exchange Commission on May 5, 2016 (the “Original Form 10-Q”). The restatement is the result of a misapplication of the accounting guidance in Accounting Standards Codification (“ASC”) No. 605, “Revenue Recognition” related to accounting for rebate obligations on government payer and managed care contracts. We also reversed an out-of-period adjustment related to a stock option modification previously recorded during the three months ended March 31, 2016 that related to the fourth quarter of 2015. This resulted in a decrease in operating expenses of $1,500,000 for the three months ended March 31, 2016 and a corresponding increase in operating expenses during the three months ended December 31, 2015. We assessed the impact of these errors on our prior unaudited condensed consolidated financial statements and concluded that the impact was material to these unaudited condensed consolidated financial statements. In order to correctly present net revenue and operating expenses in the appropriate periods during 2016 and 2015, we have restated the unaudited condensed consolidated financial information included herein. We also reclassified certain prior period amounts to conform with current period presentation. Effects of Restatement on Previously Filed March 31, 2016 Form 10-Q The effect of the restatement on the previously filed unaudited condensed consolidated balance sheets as of March 31, 2016 and 2015 is as follows, in thousands: March 31, 2016 March 31, 2015 As Reported Reclassification Restatement As Restated As Reported Reclassification Restatement As Restated Accounts receivable, net $ 20,963 $ (300 ) $ — $ 20,663 $ 34,176 $ (2,559 ) $ — $ 31,617 Prepaid expenses and other current assets 3,918 (1,156 ) 1,315 4,077 2,734 2,559 689 5,982 Deferred income tax assets, net — — — — 8,479 (8,479 ) — — Total current assets 220,750 (1,456 ) 1,315 220,609 182,085 (8,479 ) 689 174,295 Deferred income tax assets, net 17,046 — 1,146 18,192 4,874 8,479 282 13,635 Total assets 325,022 (1,456 ) 2,461 326,027 247,214 — 971 248,185 Accounts payable and accrued expenses 25,746 (1,156 ) — 24,590 36,578 (8,144 ) — 28,434 Accrued sales allowances 24,994 (300 ) 5,048 29,742 15,215 — 6,111 21,326 Accrued litigation award and settlements 9,567 — — 9,567 — 8,144 — 8,144 Total current liabilities 67,546 (1,456 ) 5,048 71,138 58,802 — 6,111 64,913 Uncertain income tax position 7,481 — (91 ) 7,390 3,778 — (42 ) 3,736 Total liabilities 75,027 (1,456 ) 4,957 78,528 62,580 — 6,069 68,649 Additional paid in capital 239,433 — (6 ) 239,427 227,327 (356 ) (1,019 ) 225,952 Retained earnings (accumulated deficit) 9,854 — (2,490 ) 7,364 (43,033 ) — (4,079 ) (47,112 ) Total stockholders’ equity 249,995 — (2,496 ) 247,499 184,634 — (5,098 ) 179,536 Total liabilities and stockholders’ equity $ 325,022 $ (1,456 ) $ 2,461 $ 326,027 $ 247,214 $ — $ 971 $ 248,185 The effect of the restatement on the previously filed unaudited condensed consolidated statements of income and comprehensive income for the three months ended March 31, 2016 and 2015 is as follows, in thousands (except share and per share data): Three Months Ended March 31, 2016 Three Months Ended March 31, 2015 As Reported Reclassification Restatement As Restated As Reported Reclassification Restatement As Restated Net revenue $ 61,962 $ — $ (1,541 ) $ 60,421 $ 70,770 $ — $ (3,078 ) $ 67,692 Gross profit 57,324 — (1,541 ) 55,783 64,395 — (3,078 ) 61,317 Research and development expenses 20,535 — (1,500 ) 19,035 10,602 — — 10,602 Total operating expenses 55,033 — (1,500 ) 53,533 52,764 — — 52,764 Operating income 2,291 — (41 ) 2,250 11,631 — (3,078 ) 8,553 Income before income taxes 2,565 — (41 ) 2,524 11,756 — (3,078 ) 8,678 Less: income tax expense 131 — 103 234 3,733 — (922 ) 2,811 Net income 2,434 — (144 ) 2,290 8,023 — (2,156 ) 5,867 Total comprehensive income $ 2,600 — $ (144 ) $ 2,456 $ 8,051 — $ (2,156 ) $ 5,895 Net income per common share: Basic $ 0.03 $ — $ — $ 0.03 $ 0.11 $ — $ (0.03 ) $ 0.08 Diluted $ 0.03 $ — $ — $ 0.03 $ 0.11 $ — $ (0.03 ) $ 0.08 The effect of the restatement on the previously filed unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2016 and 2015 is as follows, in thousands: Three Months Ended March 31, 2016 Three Months Ended March 31, 2015 As Reported Reclassification Restatement As Restated As Reported Reclassification Restatement As Restated Net income $ 2,434 $ — $ (144 ) $ 2,290 $ 8,023 $ — $ (2,156 ) $ 5,867 Stock-based compensation 5,626 — (1,500 ) 4,126 3,720 — — 3,720 Deferred income tax benefit, net (715 ) — 130 (585 ) (1,140 ) — 198 (942 ) Excess tax benefits on stock options and awards (108 ) — (545 ) (653 ) (4,069 ) 3 465 (3,601 ) Amortization of investment (premium) discount — 569 — 569 — 194 — 194 Change in accounts receivable 27,496 (887 ) — 26,609 (7,632 ) (483 ) — (8,115 ) Change in inventories 9,474 (11,139 ) — (1,665 ) (455 ) (624 ) — (1,079 ) Change in prepaid expenses and other current assets (11,083 ) 12,294 (1,315 ) (104 ) (666 ) 1,107 (655 ) (214 ) Change in accounts payable, accrued expenses and other current liabilities (22,361 ) (267 ) 2,829 (19,799 ) 17,197 (8,004 ) 2,613 11,806 Change in accrued litigation award and settlements — — — — — 8,000 — 8,000 Net cash provided by operating activities 12,290 570 (545 ) 12,315 16,194 193 465 16,852 Purchase of investments (3,289 ) (19,285 ) — (22,574 ) (6,602 ) (3,867 ) — (10,469 ) Proceeds from sales of investments — 2,108 — 2,108 371 (371 ) — — Proceeds from maturity of investments — 16,607 — 16,607 — 4,045 — 4,045 Purchases of property and equipment (2,763 ) — — (2,763 ) (5,191 ) — — (5,191 ) Net cash used in investing activities (6,052 ) (570 ) — (6,622 ) (11,422 ) (193 ) — (11,615 ) Excess tax benefits on stock options and awards 108 — 545 653 4,069 (3 ) (465 ) 3,601 Proceeds from exercise of stock options 1,310 — — 1,310 3,127 3 — 3,130 Net cash (used in) provided by financing activities $ (11,933 ) $ — $ 545 $ (11,388 ) $ 7,196 $ — $ (465 ) $ 6,731 Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, to reduce complexity in accounting standards involving several aspects of the accounting for employee share-based payment transactions, including (1) the income tax consequences, (2) classification of awards as either equity or liabilities, and (3) classification on the statement of cash flows. The amendments will be effective for financial statements issued for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and early adoption is permitted. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition, amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively, amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively, and amendments related to the presentation of excess tax benefits on the statement of cash flows can be applied using either a prospective transition method or a retrospective transition method. An entity that elects early adoption must adopt all of the amendments in the same period. We are currently evaluating the impact of these amendments on its financial statements. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed below). We are currently evaluating the impact of these amendments on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases: (Topic 842), to provide guidance on recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements, specifically differentiating between different types of leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from all leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases. However, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases should be recognized in the balance sheet. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. The amendments will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. These practical expedients relate to the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous GAAP unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous GAAP. We are currently evaluating the impact of these amendments on its financial statements. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amended the Financial Instruments topic of the Accounting Standards Codification to address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The amendments will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is not permitted. These amendments should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption. We are is currently evaluating the impact of these amendments on its financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. As amended by the FASB in July 2015, the standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2018. In July 2015, the FASB issued guidance that requires entities to measure most inventory at the lower of cost and NRV, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is measured at the lower of cost and NRV, which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The guidance is effective for annual periods beginning after December 15, 2016, and interim periods therein. Early application is permitted. We are currently evaluating the impact of adoption of this guidance on our financial position and results of operations.

Revenue Recognition _Text Block

Revenue Recognition [Text Block]	3 Months Ended
	Mar. 31, 2016
Revenue Recognition [Text Block]	2. Revenue Recognition We recognize revenue from the sale of Subsys. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured. Subsys Subsys was commercially launched in March 2012, and is monitored by an FDA mandated REMS program known as the TIRF REMS. We sell Subsys in the United States to wholesale pharmaceutical distributors and directly to retail pharmacies, collectively our customers, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. Subsys currently has a shelf life of 36 months from the date of manufacture. We record revenue for Subsys at the time the wholesaler receives the shipment. We recognize estimated product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future discounts taken. In certain cases, such as patient assistance programs, we recognize the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, we may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Our product sales allowances include: Product Returns. Because of the shelf life of our products and our return policy of issuing credits on returned product that is within six months before and up to 12 months after the product expiration date, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. Accordingly, we may have to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment. The allowance for product returns is included in accrued sales allowances. Wholesaler Discounts. Prompt Pay Discounts Patient Discount Programs Rebates Chargebacks.

Investment _Text Block_

Investment [Text Block]	3 Months Ended
	Mar. 31, 2016
Investment [Text Block]	3. Short-Term and Long-Term Investments Our policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs, avoids inappropriate concentrations and delivers an appropriate yield in relationship to our investment guidelines and market conditions. Short-term and long-term investments consist of corporate and various government agency and municipal debt securities, as well as certificates of deposit that have maturity dates that are greater than 90 days. Certificates of deposit are carried at cost which approximates fair value. We classify our marketable securities as available-for-sale Investments — Debt and Equity Securities Available-for-sale available-for-sale available-for-sale Investments consisted of the following at March 31, 2016 (in thousands): Cost Unrealized Gains Unrealized Losses Other- Than- Temporary Impairment Losses Fair Value Cash and Short-term Investments Long-term Investments Cash $ 53,683 $ — $ — $ — $ 53,683 $ 53,683 $ — $ — Money market securities 19,003 — — — 19,003 19,003 — — Certificates of deposit 29,523 — — — 29,523 — 19,642 9,881 Marketable securities: Corporate securities 29,374 13 (16 ) — 29,371 175 24,259 4,937 Federal agency securities 18,053 3 (10 ) — 18,046 899 10,396 6,751 Municipal securities 50,421 36 (12 ) — 50,445 60 35,511 14,874 Total marketable securities 97,848 52 (38 ) — 97,862 1,134 70,166 26,562 $ 200,057 $ 52 $ (38 ) $ — $ 200,071 $ 73,820 $ 89,808 $ 36,443 Investments consisted of the following at December 31, 2015 (in thousands): Cost Unrealized Gains Unrealized Losses Other- Than- Temporary Impairment Losses Fair Value Cash and Short-term Investments Long-term Investments Cash $ 55,987 $ — $ — $ — $ 55,987 $ 55,987 $ — $ — Money market securities 20,373 — — — 20,373 20,373 — — Certificates of deposit 26,223 — — — 26,223 — 16,637 9,586 Marketable securities: Corporate securities 27,186 — (68 ) — 27,118 1,621 19,181 6,316 Federal agency securities 18,823 — (65 ) — 18,758 — 10,129 8,629 Municipal securities 53,870 16 (35 ) — 53,851 1,534 33,629 18,688 Total marketable securities 99,879 16 (168 ) — 99,727 3,155 62,939 33,633 $ 202,462 $ 16 $ (168 ) $ — $ 202,310 $ 79,515 $ 79,576 $ 43,219 The amortized cost and estimated fair value of the marketable securities at March 31, 2016, by maturity, are shown below (in thousands): March 31, 2016 December 31, 2015 Amortized Cost Fair Value Amortized Cost Fair Value Marketable securities: Due in one year or less $ 71,310 $ 71,300 $ 66,148 $ 66,094 Due after one year through 5 years 26,538 26,562 33,731 33,633 Due after 5 years through 10 years — — — — Due after 10 years — — — — $ 97,848 $ 97,862 $ 99,879 $ 99,727 The following table shows the gross unrealized losses and the fair value of our investments, with unrealized losses that are not deemed to be other-than-temporarily impaired aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position at March 31, 2016 (in thousands): March 31, 2016 December 31, 2015 Less Than 12 Months Greater Than 12 Less Than 12 Months Greater Than 12 Fair Unrealized Loss Fair Unrealized Loss Fair Unrealized Loss Fair Unrealized Loss Marketable securities: Corporate securities $ 16,945 $ (16 ) $ — $ — $ 25,137 $ (68 ) $ — $ — Federal agency securities 9,408 (10 ) — — 18,759 (65 ) — — Municipal securities 15,872 (12 ) — — 22,981 (35 ) — — $ 42,225 $ (38 ) $ — $ — $ 66,877 $ (168 ) $ — $ — As of March 31, 2016, we have concluded that all the unrealized losses on our marketable securities are temporary in nature. Marketable securities are reviewed quarterly for possible other-than-temporary impairment. This review includes an analysis of the facts and circumstances of each individual investment such as the severity of loss, the expectation for that security’s performance and the creditworthiness of the issuer. Additionally, we do not intend to sell, and it is not probable that we will be required to sell, any of the securities before the recovery of their amortized cost basis.

Fair Value Disclosures _Text Bl

Fair Value Disclosures [Text Block]	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Text Block]	4. Fair Value Measurement FASB ASC No. 820, “Fair Value Measurement,” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. At March 31, 2016, we held short-term and long-term investments, as discussed in Note 3, that are required to be measured at fair value on a recurring basis. All available-for-sale Available-for-sale Our investments measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 at March 31, 2016 and December 31, 2015 were as follows (in thousands): Fair Value Measurement at Reporting Date March 31, Quoted Prices in active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Marketable securities: Corporate securities $ 29,371 $ — $ 29,371 $ — Federal agency securities 18,046 — 18,046 — Municipal securities 50,445 — 50,445 — Total assets measured at fair value $ 97,862 $ — $ 97,862 $ — Fair Value Measurement at Reporting Date December 31, Quoted Prices in active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Marketable securities: Corporate securities $ 27,118 $ — $ 27,118 $ — Federal agency securities 18,758 — 18,758 — Municipal securities 53,851 — 53,851 — Total assets measured at fair value $ 99,727 $ — $ 99,727 $ —

Inventory Disclosure _Text Bloc

Inventory Disclosure [Text Block]	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Text Block]	5. Inventories Inventories are stated at lower of cost or market. Cost, which includes amounts related to materials and costs incurred by our contract manufacturers, is determined on a first-in, first-out The components of inventories, net of allowances, are as follows (in thousands): March 31, 2016 December 31, 2015 Finished goods $ 30,089 $ 28,216 Work-in-process 6,262 7,018 Raw materials and supplies 7,029 6,481 Total inventories 43,380 41,715 Less: non-current (11,139 ) — $ 32,241 $ 41,715 As of March 31, 2016 and December 31, 2015, raw materials inventories consisted of raw materials used in the manufacture of the API in our U.S.-based, state-of-the-art Work-in-process in-process Non-current work-in-process

Commitments and Contingencies D

Commitments and Contingencies Disclosure [Text Block]	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Text Block]	6. Commitments and Contingencies Legal Matters Other than the matters that we have disclosed below, we from time to time become involved in various ordinary course legal and administrative proceedings, which include intellectual property, commercial, governmental and regulatory investigations, employee related issues and private litigation, which we do not currently believe are either individually or collectively material. As legal and governmental proceedings are inherently unpredictable and, in part, beyond our control, unless otherwise indicated, we cannot currently reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss, or range of loss, if any, that may result from these proceedings. A future adverse outcome in any of these proceedings could have a material adverse effect on our business, financial condition, results of operations and cash flows, and could cause the market value of our common stock to decline. Government Proceedings Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. The following is a brief description of pending governmental investigations which we believe are potentially material at this time. It is possible that criminal charges and substantial payments, fines and/or civil penalties or damages could result from any government investigation or proceeding, as well as a corporate integrity agreement or similar government mandated compliance document, whether we deem an investigation to be material or not at this time. Department of Health and Human Services Investigation. HIPPA Investigation. On or about June 23, 2015, a nurse practitioner located in Connecticut, who served on our speaker bureau in connection with our speaker programs designed to educate and promote product awareness and safety for external health care providers, pled guilty to violating the federal Anti-Kickback Statute in connection with payments of approximately $83,000 from us. On or about February 18, 2016, one of our former sales employees located in Alabama pled guilty to a conspiracy to violate the federal Anti-Kickback Statute in regards to two Alabama health care professionals who prescribed our product Subsys. Those two Alabama health care professionals served on our speaker bureau in connection with our speaker programs designed to educate and promote product awareness and safety for external health care providers. We continue to assess these matters to ensure we have an effective compliance program. State Related Investigations. In connection with the investigation by the ODOJ we have entered into a settlement agreement with the ODOJ referred to as an AVC, and have made monetary payments totaling approximately $1,100,000. The AVC requires us to maintain certain controls and processes around our promotional and sales activity related to Subsys in Oregon. This AVC expressly provides that we do not admit any violation of law or regulation. This settlement was reached as result of our cooperation with the ODOJ’s investigation and after producing documents in response to certain CIDs and related requests for information from the ODOJ. All monetary payments in connection with this settlement were made prior to December 31, 2015. Investigations of Physicians. Opioid Litigation With the exception of the ODOJ investigation which we have quantified above, we believe a loss from an unfavorable outcome of these governmental proceedings is reasonably possible and an estimate of the amount or range of loss from an unfavorable outcome is not determinable at these early stages. We believe we have meritorious legal positions and will continue to represent our interests vigorously in these matters. However, responding to government investigations has and could continue to burden us with substantial legal costs in connection with defending any claims raised. Any potential resulting fines, restitution, damages and penalties, settlement payments, pleas or exclusion from federal health care programs or other administrative actions, as well as any related actions brought by shareholders or other third parties, could have a material adverse effect on our financial position, results of operations or cash flows. Additionally, these matters could also have a negative impact on our reputation and divert the attention of our management from operating our business. Federal Securities Litigation On or about February 2, 2016, a complaint (captioned Richard Di Donato v. Insys Therapeutics, Inc., Case 2:16-cv-00302-NVW) was filed in the Arizona District Court, against us and certain of our current and former officers. This complaint was brought as a purported class action, on behalf of purchasers of our common stock between March 3, 2015 and January 25, 2016. In general, the plaintiffs allege that the defendants violated federal securities laws by making intentionally false and misleading statements regarding our business and operations, therefore artificially inflating the price of our common stock. The plaintiffs seek unspecified monetary damages and other relief. We intend to vigorously defend this claim. General Litigation and Disputes Kottayil vs. Insys Pharma, Inc. In February 2010, Insys Pharma and the other defendants answered and filed counter-claims to Dr. Kottayil’s amended complaint. The counter-claims include actions for breach of fiduciary duty, fraud and negligent misrepresentations and omissions with respect to the time during which Dr. Kottayil was employed at Insys Pharma. The counter-claims, among other relief, sought compensatory and punitive damages. Discovery on all of the foregoing claims was completed and a trial was scheduled to commence on January 27, 2014; however, on January 22, 2014, the court vacated the trial and granted plaintiffs leave to file an amended complaint to add Insys Therapeutics, Inc. as a defendant. On January 29, 2014, the plaintiffs filed a second amended complaint in the Arizona Superior Court in which Insys Therapeutics, Inc. was also named as defendant in this lawsuit. This amended complaint filed by plaintiffs re-alleged substantially the same claims set forth in the prior complaint, except that plaintiffs also alleged that they were entitled to rescissory damages, added our majority stockholder, a private trust, as a defendant to the breach of fiduciary duty claim and revised their fraud claim against the Insys Pharma director defendants. On February 25, 2014, we filed a Motion to Dismiss the Kottayil Plantiffs’ claims for a statutory and common law appraisal. The motion was denied on May 2, 2014. The trial commenced on December 1, 2014 with the evidence phase of the trial completed on January 29, 2015. On June 8, 2015, the court issued findings of fact and conclusions of law in its final trial ruling. Specifically, the court found (i) in favor of Insys Pharma, our majority stockholder, a private trust and four of the Insys Pharma directors who were on the board in July 2008 on plaintiffs’ claim for breach of fiduciary duty arising out of transactions the board approved in July 2008, (ii) found in favor of plaintiffs and against Insys Pharma, Inc., our majority stockholder, a private trust and three of the Insys Pharma directors who were on the board in June 2009 on plaintiffs’ claims under Delaware law and for breach of fiduciary duties arising out of the reverse stock split the board approved in June 2009 in the amount of $7,317,450, along with pre-judgment and post-judgment interest and court costs, (iii) found in favor of two of the Insys Pharma directors who were on the Insys Pharma board as of June 2009 and against plaintiffs on plaintiffs’ breach of fiduciary duty claims, (iv) found in favor of Insys Pharma and against plaintiff (Kottayil) on his claim for rescission of the patent application assignments that he entered in favor of Insys Pharma before and after his employment terminated, (v) found in favor of Insys Therapuetics, Inc. and against plaintiff on plaintiffs’ claims of successor liability and fraudulent transfer, and (vi) found in favor of Kottayil and against Insys Pharma on Insys Pharma’s counterclaims of breach of fiduciary duty, fraud, and negligent misrepresentation. On October 2, 2015, the court entered a final judgment, awarding plaintiffs the amount of $7,317,450, along with pre-judgment interest from June 2, 2009, and post-judgment interest, from October 2, 2015, at the rate of 4.25% per annum, compounded quarterly and taxable costs in the amount of $93,163. On the same date, the court denied Kottayil’s request to submit an application for attorneys’ fees for his defense of the Insys Pharma counterclaims, finding that the request was premature. On October 20, 2015, plaintiffs appealed the foregoing judgment and on November 4, 2015, Insys Pharma and the other defendants against whom judgment was entered filed a notice of cross-appeal. The appeal and cross-appeal remain pending before the Court of Appeals for the State of Arizona. Plaintiffs have filed their opening brief and we have filed our answering brief and opening brief on cross-appeal. The Plaintiffs’ deadline to file their combined reply in support of their appeal and answering brief for the cross-appeal is June 20, 2016. As a result of the final ruling, we have accrued $9,567,000 at March 31, 2016 including $2,249,000 of estimated pre-and post-judgement interest. The final outcome of the appeal which could cause the estimates to vary materially from the final award. On or around November 1, 2015 we received a notice from Dr. Kottayil’s attorneys demanding indemnification for legal and other defense costs alleged to have been incurred in connection with Dr. Kottayil’s defense of the Insys Pharma counterclaims in the amount of $3,630,000. We are in the process of assessing the merit of such claims as well as evaluating the basis for the costs claimed. Because of the uncertainty surrounding the ultimate outcome we have not accrued for this claim at this time; however, we believe that it is reasonably possible that there may be a material loss associated with this claim and we currently estimate the range of the reasonably possible loss to be between $0 and the $3,630,000 claimed. Except as it pertains to the $9,567,000 accrued for the dispute with Dr. Kottayil and the potential for damages in the Federal Securities litigation that we believe should be sufficiently covered by our director and officers insurance policies (once we have met any applicable retainage requirement under the applicable policy), we believe that the probability of unfavorable outcome or loss related to all of the above litigation matters and an estimate of the amount or range of loss, if any, from an unfavorable outcome are not determinable at this time. We believe we have meritorious legal positions and will continue to represent our interests vigorously in these matters but the range possible outcomes on these matters is very broad and we are not able to provide a reasonable estimate of our potential liability, if any, nor are we able to predict the outcome of each litigation matter. Responding to each of these litigation matters, defending any claims raised, and any resulting fines, restitution, damages and penalties, or settlement payments as well as any related actions brought by shareholders or other third parties, could have a material impact on our reputation, business and financial condition and divert the attention of our management from operating our business. Patent-Related Matters. Wayne Automatic Fire Sprinklers Material Agreements In April 2015, we entered into an amendment to our manufacturing and supply agreement with DPT, which extends our existing manufacturing and supply agreement to produce Subsys until the end of 2020. In addition to extending the term, this amendment added certain minimum purchase commitments. On October 30, 2015, we entered into an amended and restated supply, development & exclusive licensing agreement with Aptar which, among other things, extended our exclusive supply rights to the current sublingual device, currently utilized by Subsys, as well any new device(s) jointly developed by the two companies for a period of seven years. In addition to extending the term, this amendment added certain minimum purchase commitments and requires certain tiered royalties as a percentage of net revenue to be paid by us ranging from less than one percent to the low single digits, commencing in March 2016 through the term of this agreement, from our sales of Subsys and future products that use the Aptar spray device technology. The following table sets forth our aggregate minimum purchase commitments with DPT and Aptar under these agreements (in thousands): Years ending December 31, Remainder of 2016 $ 1,825 2017 10,450 2018 14,650 2019 18,260 2020 20,840 Thereafter 4,330 Total $ 70,355

Disclosure of Compensation Rela

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Stock-based Compensation Amounts recognized in the condensed consolidated statements of income and comprehensive income with respect to our stock-based compensation plans were as follows (in thousands): Three Months Ended March 31, 2016 2015 (As Restated) Research and development $ 861 $ 341 General and administrative 3,265 3,379 Total cost of stock-based compensation $ 4,126 $ 3,720 As of March 31, 2016, we expected to recognize $39,839,000 of stock-based compensation for outstanding options over a weighted-average period of 2.9 years. The following table summarizes stock option activity as of December 31, 2015 and for the three months ended March 31, 2016: Weighted Average Weighted Remaining Aggregate Number of Average Exercise Contractual Term (in Intrinsic Value Vested and exercisable as of December 31, 2015 3,772,736 $ 6.91 Outstanding as of December 31, 2015 7,138,089 $ 12.33 Granted 364,000 $ 16.69 Cancelled (152,835 ) $ 15.98 Exercised (265,325 ) $ 4.94 Outstanding as of March 31, 2016 7,083,929 $ 12.75 7.6 $ 45.4 Vested and exercisable as of March 31, 2016 3,837,871 $ 7.76 6.8 $ 36.6 Cash received from option exercises under all share-based payment arrangements for the three months ended March 31, 2016 and 2015 was $1,310,000 and $3,130,000, respectively. For the three months ended March 31, 2016 and 2015, we recorded net reductions of $653,000 and $3,601,000, respectively, of our federal and state income tax liability, with an offsetting credit to additional paid-in capital, resulting from the excess tax benefits of stock options.

Earnings Per Share _Text Block_

Earnings Per Share [Text Block]	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Text Block]	8. Net Income per Share Basic net income per common share is computed by dividing the net income allocable to the common stockholders by the weighted average number of common shares outstanding during the period. The diluted income per share further includes any common shares available to be issued upon exercise of outstanding stock options if such inclusion would be dilutive. The following table sets forth the computation of basic and diluted net income per common share (dollars in thousands, except per share amounts): Three Months Ended March 31, 2016 2015 (As Restated) Historical net income per share - Basic Numerator: Net income $ 2,290 $ 5,867 Denominator: Weighted average number of common shares outstanding 71,592,089 70,916,828 Basic net income per common share $ 0.03 $ 0.08 Historical net income per share - Diluted Numerator: Net income $ 2,290 $ 5,867 Denominator: Weighted average number of common shares outstanding 71,592,089 70,916,828 Effect of dilutive stock options 2,870,789 4,001,490 Weighted average number of common shares outstanding 74,462,878 74,918,318 Diluted net income per common share $ 0.03 $ 0.08 Anti-dilutive share equivalents included 3,419,359 and 1,584,504 outstanding stock options as of March 31, 2016 and 2015, respectively.

Concentration Risk Disclosure _

Concentration Risk Disclosure [Text Block]	3 Months Ended
	Mar. 31, 2016
Concentration Risk Disclosure [Text Block]	9. Product Lines, Concentration of Credit Risk and Significant Customers We are engaged in the business of developing and selling pharmaceutical products. In 2016, we have one product line, Subsys. Our chief operating decision-maker evaluates revenues based on product lines. The following tables summarize our net revenue by product line, as well as the percentages of revenue by route to market (in thousands): Net Revenue by Three Months Ended March 31, 2016 2015 (As Restated) Subsys $ 60,421 $ 67,462 Dronabinol SG Capsule — 230 Total net revenue $ 60,421 $ 67,692 Percent of Revenue by Route to Three Months Ended March 31, 2016 2015 Pharmaceutical wholesalers 73 % 100 % Specialty pharmaceutical retailers 27 % 0 % 100 % 100 % All our products are sold in the United States of America. Product shipments to our three largest pharmaceutical wholesalers accounted for 21%, 19% and 16% of total shipments and product shipments to one specialty pharmaceutical retailer accounted for 27% of total shipments for the three months ended March 31, 2016. Product shipments to our four largest pharmaceutical wholesalers accounted for 28%, 23%, 19% and 18% of total shipments for the three months ended March 31, 2015. Our two largest pharmaceutical wholesalers’ accounts receivable balances accounted for 25% and 25% of gross accounts receivable and one specialty pharmaceutical retailers’ accounts receivable balance accounted for 33% of gross accounts receivable balance as of March 31, 2016. Our four largest pharmaceutical wholesalers’ accounts receivable balances accounted for 20%, 19%, 17% and 14% of gross accounts receivable as of December 31, 2015.

Organization, Consolidation a16

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] (Policies)	3 Months Ended
	Mar. 31, 2016
Restatement of Financial Statements	Restatement of Financial Statements We are filing this Amendment No. 1 to our Quarterly Report on Form 10-Q (the “Amended Form 10-Q”) to restate and amend our previously issued, unaudited condensed consolidated financial statements and related financial information as of March 31, 2016 and 2015 and for the quarters ended March 31, 2016 and 2015, which was originally filed with the U.S. Securities and Exchange Commission on May 5, 2016 (the “Original Form 10-Q”). The restatement is the result of a misapplication of the accounting guidance in Accounting Standards Codification (“ASC”) No. 605, “Revenue Recognition” related to accounting for rebate obligations on government payer and managed care contracts. We also reversed an out-of-period adjustment related to a stock option modification previously recorded during the three months ended March 31, 2016 that related to the fourth quarter of 2015. This resulted in a decrease in operating expenses of $1,500,000 for the three months ended March 31, 2016 and a corresponding increase in operating expenses during the three months ended December 31, 2015. We assessed the impact of these errors on our prior unaudited condensed consolidated financial statements and concluded that the impact was material to these unaudited condensed consolidated financial statements. In order to correctly present net revenue and operating expenses in the appropriate periods during 2016 and 2015, we have restated the unaudited condensed consolidated financial information included herein. We also reclassified certain prior period amounts to conform with current period presentation. Effects of Restatement on Previously Filed March 31, 2016 Form 10-Q The effect of the restatement on the previously filed unaudited condensed consolidated balance sheets as of March 31, 2016 and 2015 is as follows, in thousands: March 31, 2016 March 31, 2015 As Reported Reclassification Restatement As Restated As Reported Reclassification Restatement As Restated Accounts receivable, net $ 20,963 $ (300 ) $ — $ 20,663 $ 34,176 $ (2,559 ) $ — $ 31,617 Prepaid expenses and other current assets 3,918 (1,156 ) 1,315 4,077 2,734 2,559 689 5,982 Deferred income tax assets, net — — — — 8,479 (8,479 ) — — Total current assets 220,750 (1,456 ) 1,315 220,609 182,085 (8,479 ) 689 174,295 Deferred income tax assets, net 17,046 — 1,146 18,192 4,874 8,479 282 13,635 Total assets 325,022 (1,456 ) 2,461 326,027 247,214 — 971 248,185 Accounts payable and accrued expenses 25,746 (1,156 ) — 24,590 36,578 (8,144 ) — 28,434 Accrued sales allowances 24,994 (300 ) 5,048 29,742 15,215 — 6,111 21,326 Accrued litigation award and settlements 9,567 — — 9,567 — 8,144 — 8,144 Total current liabilities 67,546 (1,456 ) 5,048 71,138 58,802 — 6,111 64,913 Uncertain income tax position 7,481 — (91 ) 7,390 3,778 — (42 ) 3,736 Total liabilities 75,027 (1,456 ) 4,957 78,528 62,580 — 6,069 68,649 Additional paid in capital 239,433 — (6 ) 239,427 227,327 (356 ) (1,019 ) 225,952 Retained earnings (accumulated deficit) 9,854 — (2,490 ) 7,364 (43,033 ) — (4,079 ) (47,112 ) Total stockholders’ equity 249,995 — (2,496 ) 247,499 184,634 — (5,098 ) 179,536 Total liabilities and stockholders’ equity $ 325,022 $ (1,456 ) $ 2,461 $ 326,027 $ 247,214 $ — $ 971 $ 248,185 The effect of the restatement on the previously filed unaudited condensed consolidated statements of income and comprehensive income for the three months ended March 31, 2016 and 2015 is as follows, in thousands (except share and per share data): Three Months Ended March 31, 2016 Three Months Ended March 31, 2015 As Reported Reclassification Restatement As Restated As Reported Reclassification Restatement As Restated Net revenue $ 61,962 $ — $ (1,541 ) $ 60,421 $ 70,770 $ — $ (3,078 ) $ 67,692 Gross profit 57,324 — (1,541 ) 55,783 64,395 — (3,078 ) 61,317 Research and development expenses 20,535 — (1,500 ) 19,035 10,602 — — 10,602 Total operating expenses 55,033 — (1,500 ) 53,533 52,764 — — 52,764 Operating income 2,291 — (41 ) 2,250 11,631 — (3,078 ) 8,553 Income before income taxes 2,565 — (41 ) 2,524 11,756 — (3,078 ) 8,678 Less: income tax expense 131 — 103 234 3,733 — (922 ) 2,811 Net income 2,434 — (144 ) 2,290 8,023 — (2,156 ) 5,867 Total comprehensive income $ 2,600 — $ (144 ) $ 2,456 $ 8,051 — $ (2,156 ) $ 5,895 Net income per common share: Basic $ 0.03 $ — $ — $ 0.03 $ 0.11 $ — $ (0.03 ) $ 0.08 Diluted $ 0.03 $ — $ — $ 0.03 $ 0.11 $ — $ (0.03 ) $ 0.08 The effect of the restatement on the previously filed unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2016 and 2015 is as follows, in thousands: Three Months Ended March 31, 2016 Three Months Ended March 31, 2015 As Reported Reclassification Restatement As Restated As Reported Reclassification Restatement As Restated Net income $ 2,434 $ — $ (144 ) $ 2,290 $ 8,023 $ — $ (2,156 ) $ 5,867 Stock-based compensation 5,626 — (1,500 ) 4,126 3,720 — — 3,720 Deferred income tax benefit, net (715 ) — 130 (585 ) (1,140 ) — 198 (942 ) Excess tax benefits on stock options and awards (108 ) — (545 ) (653 ) (4,069 ) 3 465 (3,601 ) Amortization of investment (premium) discount — 569 — 569 — 194 — 194 Change in accounts receivable 27,496 (887 ) — 26,609 (7,632 ) (483 ) — (8,115 ) Change in inventories 9,474 (11,139 ) — (1,665 ) (455 ) (624 ) — (1,079 ) Change in prepaid expenses and other current assets (11,083 ) 12,294 (1,315 ) (104 ) (666 ) 1,107 (655 ) (214 ) Change in accounts payable, accrued expenses and other current liabilities (22,361 ) (267 ) 2,829 (19,799 ) 17,197 (8,004 ) 2,613 11,806 Change in accrued litigation award and settlements — — — — — 8,000 — 8,000 Net cash provided by operating activities 12,290 570 (545 ) 12,315 16,194 193 465 16,852 Purchase of investments (3,289 ) (19,285 ) — (22,574 ) (6,602 ) (3,867 ) — (10,469 ) Proceeds from sales of investments — 2,108 — 2,108 371 (371 ) — — Proceeds from maturity of investments — 16,607 — 16,607 — 4,045 — 4,045 Purchases of property and equipment (2,763 ) — — (2,763 ) (5,191 ) — — (5,191 ) Net cash used in investing activities (6,052 ) (570 ) — (6,622 ) (11,422 ) (193 ) — (11,615 ) Excess tax benefits on stock options and awards 108 — 545 653 4,069 (3 ) (465 ) 3,601 Proceeds from exercise of stock options 1,310 — — 1,310 3,127 3 — 3,130 Net cash (used in) provided by financing activities $ (11,933 ) $ — $ 545 $ (11,388 ) $ 7,196 $ — $ (465 ) $ 6,731
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, to reduce complexity in accounting standards involving several aspects of the accounting for employee share-based payment transactions, including (1) the income tax consequences, (2) classification of awards as either equity or liabilities, and (3) classification on the statement of cash flows. The amendments will be effective for financial statements issued for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and early adoption is permitted. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition, amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively, amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively, and amendments related to the presentation of excess tax benefits on the statement of cash flows can be applied using either a prospective transition method or a retrospective transition method. An entity that elects early adoption must adopt all of the amendments in the same period. We are currently evaluating the impact of these amendments on its financial statements. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed below). We are currently evaluating the impact of these amendments on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases: (Topic 842), to provide guidance on recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements, specifically differentiating between different types of leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from all leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases. However, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases should be recognized in the balance sheet. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. The amendments will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. These practical expedients relate to the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous GAAP unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous GAAP. We are currently evaluating the impact of these amendments on its financial statements. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amended the Financial Instruments topic of the Accounting Standards Codification to address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The amendments will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is not permitted. These amendments should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption. We are is currently evaluating the impact of these amendments on its financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. As amended by the FASB in July 2015, the standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2018. In July 2015, the FASB issued guidance that requires entities to measure most inventory at the lower of cost and NRV, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is measured at the lower of cost and NRV, which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The guidance is effective for annual periods beginning after December 15, 2016, and interim periods therein. Early application is permitted. We are currently evaluating the impact of adoption of this guidance on our financial position and results of operations.

Organization, Consolidation a17

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] (Tables)	3 Months Ended
	Mar. 31, 2016
Effects of Restatement on Previously Filed Statements [Table Text Block]	The effect of the restatement on the previously filed unaudited condensed consolidated balance sheets as of March 31, 2016 and 2015 is as follows, in thousands: March 31, 2016 March 31, 2015 As Reported Reclassification Restatement As Restated As Reported Reclassification Restatement As Restated Accounts receivable, net $ 20,963 $ (300 ) $ — $ 20,663 $ 34,176 $ (2,559 ) $ — $ 31,617 Prepaid expenses and other current assets 3,918 (1,156 ) 1,315 4,077 2,734 2,559 689 5,982 Deferred income tax assets, net — — — — 8,479 (8,479 ) — — Total current assets 220,750 (1,456 ) 1,315 220,609 182,085 (8,479 ) 689 174,295 Deferred income tax assets, net 17,046 — 1,146 18,192 4,874 8,479 282 13,635 Total assets 325,022 (1,456 ) 2,461 326,027 247,214 — 971 248,185 Accounts payable and accrued expenses 25,746 (1,156 ) — 24,590 36,578 (8,144 ) — 28,434 Accrued sales allowances 24,994 (300 ) 5,048 29,742 15,215 — 6,111 21,326 Accrued litigation award and settlements 9,567 — — 9,567 — 8,144 — 8,144 Total current liabilities 67,546 (1,456 ) 5,048 71,138 58,802 — 6,111 64,913 Uncertain income tax position 7,481 — (91 ) 7,390 3,778 — (42 ) 3,736 Total liabilities 75,027 (1,456 ) 4,957 78,528 62,580 — 6,069 68,649 Additional paid in capital 239,433 — (6 ) 239,427 227,327 (356 ) (1,019 ) 225,952 Retained earnings (accumulated deficit) 9,854 — (2,490 ) 7,364 (43,033 ) — (4,079 ) (47,112 ) Total stockholders’ equity 249,995 — (2,496 ) 247,499 184,634 — (5,098 ) 179,536 Total liabilities and stockholders’ equity $ 325,022 $ (1,456 ) $ 2,461 $ 326,027 $ 247,214 $ — $ 971 $ 248,185 The effect of the restatement on the previously filed unaudited condensed consolidated statements of income and comprehensive income for the three months ended March 31, 2016 and 2015 is as follows, in thousands (except share and per share data): Three Months Ended March 31, 2016 Three Months Ended March 31, 2015 As Reported Reclassification Restatement As Restated As Reported Reclassification Restatement As Restated Net revenue $ 61,962 $ — $ (1,541 ) $ 60,421 $ 70,770 $ — $ (3,078 ) $ 67,692 Gross profit 57,324 — (1,541 ) 55,783 64,395 — (3,078 ) 61,317 Research and development expenses 20,535 — (1,500 ) 19,035 10,602 — — 10,602 Total operating expenses 55,033 — (1,500 ) 53,533 52,764 — — 52,764 Operating income 2,291 — (41 ) 2,250 11,631 — (3,078 ) 8,553 Income before income taxes 2,565 — (41 ) 2,524 11,756 — (3,078 ) 8,678 Less: income tax expense 131 — 103 234 3,733 — (922 ) 2,811 Net income 2,434 — (144 ) 2,290 8,023 — (2,156 ) 5,867 Total comprehensive income $ 2,600 — $ (144 ) $ 2,456 $ 8,051 — $ (2,156 ) $ 5,895 Net income per common share: Basic $ 0.03 $ — $ — $ 0.03 $ 0.11 $ — $ (0.03 ) $ 0.08 Diluted $ 0.03 $ — $ — $ 0.03 $ 0.11 $ — $ (0.03 ) $ 0.08 The effect of the restatement on the previously filed unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2016 and 2015 is as follows, in thousands: Three Months Ended March 31, 2016 Three Months Ended March 31, 2015 As Reported Reclassification Restatement As Restated As Reported Reclassification Restatement As Restated Net income $ 2,434 $ — $ (144 ) $ 2,290 $ 8,023 $ — $ (2,156 ) $ 5,867 Stock-based compensation 5,626 — (1,500 ) 4,126 3,720 — — 3,720 Deferred income tax benefit, net (715 ) — 130 (585 ) (1,140 ) — 198 (942 ) Excess tax benefits on stock options and awards (108 ) — (545 ) (653 ) (4,069 ) 3 465 (3,601 ) Amortization of investment (premium) discount — 569 — 569 — 194 — 194 Change in accounts receivable 27,496 (887 ) — 26,609 (7,632 ) (483 ) — (8,115 ) Change in inventories 9,474 (11,139 ) — (1,665 ) (455 ) (624 ) — (1,079 ) Change in prepaid expenses and other current assets (11,083 ) 12,294 (1,315 ) (104 ) (666 ) 1,107 (655 ) (214 ) Change in accounts payable, accrued expenses and other current liabilities (22,361 ) (267 ) 2,829 (19,799 ) 17,197 (8,004 ) 2,613 11,806 Change in accrued litigation award and settlements — — — — — 8,000 — 8,000 Net cash provided by operating activities 12,290 570 (545 ) 12,315 16,194 193 465 16,852 Purchase of investments (3,289 ) (19,285 ) — (22,574 ) (6,602 ) (3,867 ) — (10,469 ) Proceeds from sales of investments — 2,108 — 2,108 371 (371 ) — — Proceeds from maturity of investments — 16,607 — 16,607 — 4,045 — 4,045 Purchases of property and equipment (2,763 ) — — (2,763 ) (5,191 ) — — (5,191 ) Net cash used in investing activities (6,052 ) (570 ) — (6,622 ) (11,422 ) (193 ) — (11,615 ) Excess tax benefits on stock options and awards 108 — 545 653 4,069 (3 ) (465 ) 3,601 Proceeds from exercise of stock options 1,310 — — 1,310 3,127 3 — 3,130 Net cash (used in) provided by financing activities $ (11,933 ) $ — $ 545 $ (11,388 ) $ 7,196 $ — $ (465 ) $ 6,731

Investment _Text Block_ (Tables

Investment [Text Block] (Tables)	3 Months Ended
	Mar. 31, 2016
Available-for-sale Securities [Table Text Block]	Investments consisted of the following at March 31, 2016 (in thousands): Cost Unrealized Gains Unrealized Losses Other- Than- Temporary Impairment Losses Fair Value Cash and Short-term Investments Long-term Investments Cash $ 53,683 $ — $ — $ — $ 53,683 $ 53,683 $ — $ — Money market securities 19,003 — — — 19,003 19,003 — — Certificates of deposit 29,523 — — — 29,523 — 19,642 9,881 Marketable securities: Corporate securities 29,374 13 (16 ) — 29,371 175 24,259 4,937 Federal agency securities 18,053 3 (10 ) — 18,046 899 10,396 6,751 Municipal securities 50,421 36 (12 ) — 50,445 60 35,511 14,874 Total marketable securities 97,848 52 (38 ) — 97,862 1,134 70,166 26,562 $ 200,057 $ 52 $ (38 ) $ — $ 200,071 $ 73,820 $ 89,808 $ 36,443 Investments consisted of the following at December 31, 2015 (in thousands): Cost Unrealized Gains Unrealized Losses Other- Than- Temporary Impairment Losses Fair Value Cash and Short-term Investments Long-term Investments Cash $ 55,987 $ — $ — $ — $ 55,987 $ 55,987 $ — $ — Money market securities 20,373 — — — 20,373 20,373 — — Certificates of deposit 26,223 — — — 26,223 — 16,637 9,586 Marketable securities: Corporate securities 27,186 — (68 ) — 27,118 1,621 19,181 6,316 Federal agency securities 18,823 — (65 ) — 18,758 — 10,129 8,629 Municipal securities 53,870 16 (35 ) — 53,851 1,534 33,629 18,688 Total marketable securities 99,879 16 (168 ) — 99,727 3,155 62,939 33,633 $ 202,462 $ 16 $ (168 ) $ — $ 202,310 $ 79,515 $ 79,576 $ 43,219
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	The amortized cost and estimated fair value of the marketable securities at March 31, 2016, by maturity, are shown below (in thousands): March 31, 2016 December 31, 2015 Amortized Fair Value Amortized Fair Value Marketable securities: Due in one year or less $ 71,310 $ 71,300 $ 66,148 $ 66,094 Due after one year through 5 years 26,538 26,562 33,731 33,633 Due after 5 years through 10 years — — — — Due after 10 years — — — — $ 97,848 $ 97,862 $ 99,879 $ 99,727
Schedule of Unrealized Loss on Investments [Table Text Block]	The following table shows the gross unrealized losses and the fair value of our investments, with unrealized losses that are not deemed to be other-than-temporarily impaired aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position at March 31, 2016 (in thousands): March 31, 2016 December 31, 2015 Less Than 12 Months Greater Than 12 Less Than 12 Months Greater Than 12 Fair Unrealized Loss Fair Unrealized Loss Fair Unrealized Loss Fair Unrealized Loss Marketable securities: Corporate securities $ 16,945 $ (16 ) $ — $ — $ 25,137 $ (68 ) $ — $ — Federal agency securities 9,408 (10 ) — — 18,759 (65 ) — — Municipal securities 15,872 (12 ) — — 22,981 (35 ) — — $ 42,225 $ (38 ) $ — $ — $ 66,877 $ (168 ) $ — $ —

Fair Value Disclosures _Text 19

Fair Value Disclosures [Text Block] (Tables)	3 Months Ended
	Mar. 31, 2016
Available-for-sale Securities [Table Text Block]	Our investments measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 at March 31, 2016 and December 31, 2015 were as follows (in thousands): Fair Value Measurement at Reporting Date March 31, Quoted Prices in active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Marketable securities: Corporate securities $ 29,371 $ — $ 29,371 $ — Federal agency securities 18,046 — 18,046 — Municipal securities 50,445 — 50,445 — Total assets measured at fair value $ 97,862 $ — $ 97,862 $ — Fair Value Measurement at Reporting Date December 31, Quoted Prices in active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Marketable securities: Corporate securities $ 27,118 $ — $ 27,118 $ — Federal agency securities 18,758 — 18,758 — Municipal securities 53,851 — 53,851 — Total assets measured at fair value $ 99,727 $ — $ 99,727 $ —

Inventory Disclosure _Text Bl20

Inventory Disclosure [Text Block] (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Inventory, Current [Table Text Block]	The components of inventories, net of allowances, are as follows (in thousands): March 31, 2016 December 31, 2015 Finished goods $ 30,089 $ 28,216 Work-in-process 6,262 7,018 Raw materials and supplies 7,029 6,481 Total inventories 43,380 41,715 Less: non-current (11,139 ) — $ 32,241 $ 41,715

Commitments and Contingencies21

Commitments and Contingencies Disclosure [Text Block] (Tables)	3 Months Ended
	Mar. 31, 2016
Long-term Purchase Commitment [Table Text Block]	The following table sets forth our aggregate minimum purchase commitments with DPT and Aptar under these agreements (in thousands): Years ending December 31, Remainder of 2016 1,825 2017 10,450 2018 14,650 2019 18,260 2020 20,840 Thereafter 4,330 Total $ 70,355

Disclosure of Compensation Re22

Disclosure of Compensation Related Costs, Share-based Payments [Text Block] (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Amounts recognized in the condensed consolidated statements of income and comprehensive income with respect to our stock-based compensation plans were as follows (in thousands): Three Months Ended March 31, 2016 2015 (As Restated) Research and development $ 861 $ 341 General and administrative 3,265 3,379 Total cost of stock-based compensation $ 4,126 $ 3,720
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity as of December 31, 2015 and for the three months ended March 31, 2016: Weighted Average Weighted Remaining Aggregate Number of Average Exercise Contractual Term (in Intrinsic Value Vested and exercisable as of December 31, 2015 3,772,736 $ 6.91 Outstanding as of December 31, 2015 7,138,089 $ 12.33 Granted 364,000 $ 16.69 Cancelled (152,835 ) $ 15.98 Exercised (265,325 ) $ 4.94 Outstanding as of March 31, 2016 7,083,929 $ 12.75 7.6 $ 45.4 Vested and exercisable as of March 31, 2016 3,837,871 $ 7.76 6.8 $ 36.6

Earnings Per Share _Text Bloc23

Earnings Per Share [Text Block] (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of basic and diluted net income per common share (dollars in thousands, except per share amounts): Three Months Ended March 31, 2016 2015 (As Restated) Historical net income per share - Basic Numerator: Net income $ 2,290 $ 5,867 Denominator: Weighted average number of common shares outstanding 71,592,089 70,916,828 Basic net income per common share $ 0.03 $ 0.08 Historical net income per share - Diluted Numerator: Net income $ 2,290 $ 5,867 Denominator: Weighted average number of common shares outstanding 71,592,089 70,916,828 Effect of dilutive stock options 2,870,789 4,001,490 Weighted average number of common shares outstanding 74,462,878 74,918,318 Diluted net income per common share $ 0.03 $ 0.08

Concentration Risk Disclosure24

Concentration Risk Disclosure [Text Block] (Tables)	3 Months Ended
	Mar. 31, 2016
Revenue from External Customers by Products and Services [Table Text Block]	The following tables summarize our net revenue by product line, as well as the percentages of revenue by route to market (in thousands): Net Revenue by Three Months Ended March 31, 2016 2015 (As Restated) Subsys $ 60,421 $ 67,462 Dronabinol SG Capsule — 230 Total net revenue $ 60,421 $ 67,692
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Percent of Revenue by Route to Three Months Ended March 31, 2016 2015 Pharmaceutical wholesalers 73 % 100 % Specialty pharmaceutical retailers 27 % 0 % 100 % 100 %

Note 1 - Nature of Business and

Note 1 - Nature of Business and Basis of Presentation - Textual (Detail) $ / shares in Units, $ in Thousands	May 26, 2016$ / shares	Mar. 31, 2016USD ($)$ / shares	Dec. 31, 2015USD ($)$ / shares	Mar. 31, 2015USD ($)$ / shares
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01	$ 0.01	$ 0.01
Total operating expenses | $		$ 53,533		$ 52,764
Prior Period Adjustment [Member]
Total operating expenses | $		$ (1,500)	$ 1,500
Subsys [Member]
Number of Product Lines		1
Stockholders' Equity Note, Stock Split, Conversion Ratio	2
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.01

Note1- Effects of Restatement o

Note1- Effects of Restatement on Previously Filed Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Accounts receivable, net	$ 20,663	$ 47,272	$ 31,617
Prepaid expenses and other current assets	4,077	3,973	5,982
Total current assets	220,609	252,051	174,295
Deferred income tax assets,net	18,192	17,607	13,635
Total assets	326,027	351,285	248,185
Accounts payable and accrued expenses	24,590	35,611	28,434
Accrued sales allowances	29,742	35,033	21,326
Accrued litigation award and settlements	9,567	9,567	8,144
Total current liabilities	71,138	90,436	64,913
Uncertain income tax position	7,390	8,544	3,736
Total liabilities	78,528	98,980	68,649
Additional paid in capital	239,427	246,685	225,952
Retained earnings (accumulated deficit)	7,364	5,074	(47,112)
Total stockholders' equity	247,499	252,305	179,536	$ 163,190
Total liabilities and stockholders' equity	326,027	$ 351,285	248,185
As Reported [Member]
Accounts receivable, net	20,963		34,176
Prepaid expenses and other current assets	3,918		2,734
Deferred income tax assets,net			8,479
Total current assets	220,750		182,085
Deferred income tax assets,net	17,046		4,874
Total assets	325,022		247,214
Accounts payable and accrued expenses	25,746		36,578
Accrued sales allowances	24,994		15,215
Accrued litigation award and settlements	9,567
Total current liabilities	67,546		58,802
Uncertain income tax position	7,481		3,778
Total liabilities	75,027		62,580
Additional paid in capital	239,433		227,327
Retained earnings (accumulated deficit)	9,854		(43,033)
Total stockholders' equity	249,995		184,634
Total liabilities and stockholders' equity	325,022		247,214
Reclassification Adjustments [Member]
Accounts receivable, net	(300)		(2,559)
Prepaid expenses and other current assets	(1,156)		2,559
Deferred income tax assets,net			(8,479)
Total current assets	(1,456)		(8,479)
Deferred income tax assets,net			8,479
Total assets	(1,456)
Accounts payable and accrued expenses	(1,156)		(8,144)
Accrued sales allowances	(300)
Accrued litigation award and settlements			8,144
Total current liabilities	(1,456)
Total liabilities	(1,456)
Additional paid in capital			(356)
Total liabilities and stockholders' equity	(1,456)
Restatement Adjustments [Member]
Prepaid expenses and other current assets	1,315		689
Total current assets	1,315		689
Deferred income tax assets,net	1,146		282
Total assets	2,461		971
Accrued sales allowances	5,048		6,111
Total current liabilities	5,048		6,111
Uncertain income tax position	(91)		(42)
Total liabilities	4,957		6,069
Additional paid in capital	(6)		(1,019)
Retained earnings (accumulated deficit)	(2,490)		(4,079)
Total stockholders' equity	(2,496)		(5,098)
Total liabilities and stockholders' equity	$ 2,461		$ 971

Note1 - Effects of Restatement

Note1 - Effects of Restatement on Previously Filed Condensed Consolidated Statements of Income and Comprehensive Income (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net revenue	$ 60,421	$ 67,692
Gross profit	55,783	61,317
Research and development expenses	19,035	10,602
Total operating expenses	53,533	52,764
Operating income	2,250	8,553
Income before income taxes	2,524	8,678
Less: income tax expense	234	2,811
Net income	2,290	5,867
Total comprehensive income	$ 2,456	$ 5,895
Net income per common share:
Basic	$ 0.03	$ 0.08
Diluted	$ 0.03	$ 0.08
As Reported [Member]
Net revenue	$ 61,962	$ 70,770
Gross profit	57,324	64,395
Research and development expenses	20,535	10,602
Total operating expenses	55,033	52,764
Operating income	2,291	11,631
Income before income taxes	2,565	11,756
Less: income tax expense	131	3,733
Net income	2,434	8,023
Total comprehensive income	$ 2,600	$ 8,051
Net income per common share:
Basic	$ 0.03	$ 0.11
Diluted	$ 0.03	$ 0.11
Restatement Adjustments [Member]
Net revenue	$ (1,541)	$ (3,078)
Gross profit	(1,541)	(3,078)
Research and development expenses	(1,500)
Total operating expenses	(1,500)
Operating income	(41)	(3,078)
Income before income taxes	(41)	(3,078)
Less: income tax expense	103	(922)
Net income	(144)	(2,156)
Total comprehensive income	$ (144)	$ (2,156)
Net income per common share:
Basic		$ (0.03)
Diluted		$ (0.03)

Note1 - Effects of Restatemen28

Note1 - Effects of Restatement on Previously Filed Condensed Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net income	$ 2,290	$ 5,867
Stock-based compensation	4,126	3,720
Deferred income tax benefit,net	(585)	(942)
Excess tax benefits on stock options and awards	(653)	(3,601)
Amortization of investment (premium) discount	569	194
Change in accounts receivable	26,609	(8,115)
Change in inventories	(1,665)	(1,079)
Change in prepaid expenses and other current assets	(104)	(214)
Change in accounts payable, accrued expenses and other current liabilities	(19,799)	11,806
Change in accrued litigation award and settlements		8,000
Net cash provided by operating activities	12,315	16,852
Purchase of investments	(22,574)	(10,469)
Proceeds from sales of investments	2,108
Proceeds from maturity of investments	16,607	4,045
Purchases of property and equipment	(2,763)	(5,191)
Net cash used in investing activities	(6,622)	(11,615)
Excess tax benefits on stock options and awards	653	3,601
Proceeds from exercise of stock options	1,310	3,130
Net cash (used in) provided by financing activities	(11,388)	6,731
As Reported [Member]
Net income	2,434	8,023
Stock-based compensation	5,626	3,720
Deferred income tax benefit,net	(715)	(1,140)
Excess tax benefits on stock options and awards	(108)	(4,069)
Change in accounts receivable	27,496	(7,632)
Change in inventories	9,474	(455)
Change in prepaid expenses and other current assets	(11,083)	(666)
Change in accounts payable, accrued expenses and other current liabilities	(22,361)	17,197
Net cash provided by operating activities	12,290	16,194
Purchase of investments	(3,289)	(6,602)
Proceeds from sales of investments		371
Purchases of property and equipment	(2,763)	(5,191)
Net cash used in investing activities	(6,052)	(11,422)
Excess tax benefits on stock options and awards	108	4,069
Proceeds from exercise of stock options	1,310	3,127
Net cash (used in) provided by financing activities	(11,933)	7,196
Reclassification Adjustments [Member]
Excess tax benefits on stock options and awards		3
Amortization of investment (premium) discount	569	194
Change in accounts receivable	(887)	(483)
Change in inventories	(11,139)	(624)
Change in prepaid expenses and other current assets	12,294	1,107
Change in accounts payable, accrued expenses and other current liabilities	(267)	(8,004)
Change in accrued litigation award and settlements		8,000
Net cash provided by operating activities	570	193
Purchase of investments	(19,285)	(3,867)
Proceeds from sales of investments	2,108	(371)
Proceeds from maturity of investments	16,607	4,045
Net cash used in investing activities	(570)	(193)
Excess tax benefits on stock options and awards		(3)
Proceeds from exercise of stock options		3
Restatement Adjustments [Member]
Net income	(144)	(2,156)
Stock-based compensation	(1,500)
Deferred income tax benefit,net	130	198
Excess tax benefits on stock options and awards	(545)	465
Change in prepaid expenses and other current assets	(1,315)	(655)
Change in accounts payable, accrued expenses and other current liabilities	2,829	2,613
Net cash provided by operating activities	(545)	465
Excess tax benefits on stock options and awards	545	(465)
Net cash (used in) provided by financing activities	$ 545	$ (465)

Note 2 - Revenue Recognition -

Note 2 - Revenue Recognition - Textual (Detail)	3 Months Ended
	Mar. 31, 2016
Subsys [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Product Return, Period Prior to Expiration	180 days
Product Return, Period After Expiration	1 year
Shelf Life of Product from Date of Manufacture	3 years
Mylan Pharmaceuticals, Inc [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cash Discount, Percent	2.00%

Note 3 - Short-term and Long-te

Note 3 - Short-term and Long-term Investments (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Investment Owned, at Fair Value	$ 200,071,000	$ 202,310,000
Cash and Cash Equivalents [Member]
Investment Owned, at Fair Value	1,134,000
Short-term Investments [Member]
Investment Owned, at Fair Value	89,808,000
Other Long-term Investments [Member]
Investment Owned, at Fair Value	$ 36,443,000

Note 3 - Short-term and Long-31

Note 3 - Short-term and Long-term Investments - Summary of Investments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Amortized Cost	$ 200,057	$ 202,462
Unrealized Gains	52	16
Unrealized Losses	(38)	(168)
Other- Than- Temporary Impairment Losses	0
Investment Owned, at Fair Value	200,071	202,310
Cash and cash equivalents	73,820	79,515	$ 70,074	$ 58,106
Short-term investments	89,808	79,576	31,386
Long-term investments	36,443	43,219	$ 22,891
Cash [Member]
Amortized Cost	53,683	55,987
Other- Than- Temporary Impairment Losses	0
Investment Owned, at Fair Value	53,683	55,987
Cash and cash equivalents	53,683	55,987
Money Market Funds [Member]
Amortized Cost	19,003	20,373
Other- Than- Temporary Impairment Losses	0
Investment Owned, at Fair Value	19,003	20,373
Cash and cash equivalents	19,003	20,373
Certificates of Deposit [Member]
Amortized Cost	29,523	26,223
Other- Than- Temporary Impairment Losses	0
Investment Owned, at Fair Value	29,523	26,223
Short-term investments	19,642	16,637
Long-term investments	9,881	9,586
Corporate Debt Securities [Member]
Amortized Cost	29,374	27,186
Unrealized Gains	13
Unrealized Losses	(16)	(68)
Other- Than- Temporary Impairment Losses	0
Investment Owned, at Fair Value	29,371	27,118
Cash and cash equivalents	175	1,621
Short-term investments	24,259	19,181
Long-term investments	4,937	6,316
US Government Agencies Debt Securities [Member]
Amortized Cost	18,053	18,823
Unrealized Gains	3
Unrealized Losses	(10)	(65)
Other- Than- Temporary Impairment Losses	0
Investment Owned, at Fair Value	18,046	18,758
Cash and cash equivalents	899
Short-term investments	10,396	10,129
Long-term investments	6,751	8,629
Municipal Bonds [Member]
Amortized Cost	50,421	53,870
Unrealized Gains	36	16
Unrealized Losses	(12)	(35)
Other- Than- Temporary Impairment Losses	0
Investment Owned, at Fair Value	50,445	53,851
Cash and cash equivalents	60	1,534
Short-term investments	35,511	33,629
Long-term investments	14,874	18,688
Marketable Securities [Member]
Amortized Cost	97,848	99,879
Unrealized Gains	52	16
Unrealized Losses	(38)	(168)
Other- Than- Temporary Impairment Losses	0
Investment Owned, at Fair Value	97,862	99,727
Cash and cash equivalents	1,134	3,155
Short-term investments	70,166	62,939
Long-term investments	$ 26,562	$ 33,633

Note 3 - Short-term and Long-32

Note 3 - Short-term and Long-term Investments - Amortized Cost and Estimated Fair Value of Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Marketable securities:
Due in one year or less	$ 71,310	$ 66,148
Due in one year or less	71,300	66,094
Due after one year through 5 years	26,538	33,731
Due after one year through 5 years	26,562	33,633
Due after 5 years through 10 years
Due after 5 years through 10 years
Due after 10 years
Due after 10 years
Total	97,848	99,879
Total	$ 97,862	$ 99,727

Note 3 - Short-term and Long-33

Note 3 - Short-term and Long-term Investments - Gross Unrealized Losses (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Less Than 12 Months Fair Value	$ 42,225	$ 66,877
Less Than 12 Months Unrealized Loss	(38)	(168)
Greater Than 12 Months Fair Value	0	0
Greater Than 12 Months Unrealized Loss	0	0
Corporate Bond Securities [Member]
Less Than 12 Months Fair Value	16,945	25,137
Less Than 12 Months Unrealized Loss	(16)	(68)
Greater Than 12 Months Fair Value	0	0
Greater Than 12 Months Unrealized Loss	0	0
US Government Agencies Debt Securities [Member]
Less Than 12 Months Fair Value	9,408	18,759
Less Than 12 Months Unrealized Loss	(10)	(65)
Greater Than 12 Months Fair Value	0	0
Greater Than 12 Months Unrealized Loss	0	0
Municipal Bonds [Member]
Less Than 12 Months Fair Value	15,872	22,981
Less Than 12 Months Unrealized Loss	(12)	(35)
Greater Than 12 Months Fair Value	0	0
Greater Than 12 Months Unrealized Loss	$ 0	$ 0

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurement - Investments Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Available-for-sale securities	$ 97,862	$ 99,727
Fair Value, Inputs, Level 1 [Member]
Available-for-sale securities
Fair Value, Inputs, Level 2 [Member]
Available-for-sale securities	97,862	99,727
Fair Value, Inputs, Level 3 [Member]
Available-for-sale securities
Corporate Debt Securities [Member]
Available-for-sale securities	29,371	27,118
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale securities
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale securities	29,371	27,118
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale securities
US Government Agencies Debt Securities [Member]
Available-for-sale securities	18,046	18,758
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale securities
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale securities	18,046	18,758
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale securities
Municipal Bonds [Member]
Available-for-sale securities	50,445	53,851
Municipal Bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale securities
Municipal Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale securities	50,445	53,851
Municipal Bonds [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale securities

Note 5 - Inventories - Componen

Note 5 - Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Finished goods	$ 30,089	$ 28,216
Work-in-process	6,262	7,018
Raw materials and supplies	7,029	6,481
Total inventories	43,380	41,715
Less: non-current finished goods	(11,139)
Inventories, net	$ 32,241	$ 41,715	$ 35,236

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies - Textual (Detail) - USD ($)	Jan. 26, 2016	Nov. 01, 2015	Oct. 30, 2015	Oct. 02, 2015	Jun. 23, 2015	Jun. 08, 2015	Mar. 31, 2015	Dec. 31, 2015	Mar. 31, 2006
Litigation Settlement, Expense							$ 8,000,000
Anti-Kickback Statute Litigation [Member] | Settled Litigation [Member]
Payments In Question					$ 83,000
Oregon Department of Justice [Member] | Settled Litigation [Member]
Litigation Settlement, Amount								$ 1,100,000
Kottayil vs. Insys Pharma, Inc. [Member] | Settled Litigation [Member]
Litigation Settlement, Amount						$ (7,317,450)
Loss Contingency, Damages Awarded, Value				$ 7,317,450
Litigation Settlement, Post-Judgment Interest				4.25%
Litigation Settlement, Expense				$ 93,163
Estimated Litigation Liability									$ 9,567,000
Kottayil vs. Insys Pharma, Inc. [Member] | Settled Litigation [Member] | Settlement Interest [Member]
Estimated Litigation Liability									$ 2,249,000
Kottayil vs. Insys Pharma, Inc. [Member] | Threatened Litigation [Member]
Loss Contingency, Damages Sought, Value		$ 3,630,000
Kottayil vs. Insys Pharma, Inc. [Member] | Maximum [Member] | Threatened Litigation [Member]
Loss Contingency, Estimate of Possible Loss		3,630,000
Kottayil vs. Insys Pharma, Inc. [Member] | Minimum [Member] | Threatened Litigation [Member]
Loss Contingency, Estimate of Possible Loss		$ 0
Wayne Automatic Fire Sprinklers [Member] | Threatened Litigation [Member]
Alleged Benfits Erroneously Paid By Health Benifit Plan	$ 198,000
Term of Aptargroup, Inc Joint Agreement			7 years
Wayne Automatic Fire Sprinklers [Member] | Minimum [Member] | Threatened Litigation [Member]
Loss Contingency, Damages Sought, Value	$ 75,000

Note 6 - Commitments and Cont37

Note 6 - Commitments and Contingencies - Future Minimum Purchase Commitments (Detail)	Dec. 31, 2016USD ($)
Years ending December 31,
Remainder of 2016	$ 1,825
2,017	10,450
2,018	14,650
2,019	18,260
2,020	20,840
Thereafter	4,330
Total	$ 70,355

Note 7 - Stock-based Compensati

Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Allocated share-based compensation expense	$ 4,126	$ 3,720
Research and Development Expense [Member]
Allocated share-based compensation expense	861	341
General and Administrative Expense [Member]
Allocated share-based compensation expense	$ 3,265	$ 3,379

Note 7 - Stock-based Compensa39

Note 7 - Stock-based Compensation - Textual (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 39,839,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 292 days
Proceeds from Stock Options Exercised	$ 1,310,000	$ 3,130,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$ 653,000	$ 3,601,000

Note 7 - Stock-based Compensa40

Note 7 - Stock-based Compensation - Stock Option Activity (Detail) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Vested and exercisable as of December 31, 2015 (in shares) | shares	3,772,736
Outstanding as of December 31, 2015 (in shares) | shares	7,138,089
Granted (in shares) | shares	364,000
Cancelled (in shares) | shares	(152,835)
Exercised (in shares) | shares	(265,325)
Outstanding as of March 31, 2016 (in shares) | shares	7,083,929
Vested and exercisable as of March 31, 2016 (in shares) | shares	3,837,871
Vested and exercisable (in dollars per share) | $ / shares	$ 6.91
Outstanding (in dollars per share) | $ / shares	12.33
Granted (in dollars per share) | $ / shares	16.69
Cancelled (in dollars per share) | $ / shares	15.98
Exercised (in dollars per share) | $ / shares	4.94
Outstanding (in dollars per share) | $ / shares	12.75
Vested and exercisable | $ / shares	$ 7.76
Outstanding	7 years 219 days
Vested and exercisable	6 years 292 days
Outstanding | $	$ 45.4
Vested and exercisable | $	$ 36.6

Note 8 - Net Income Per Share -

Note 8 - Net Income Per Share - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net income	$ 2,290	$ 5,867
Weighted average number of common shares outstanding	71,592,089	70,916,828
Basic net income per common share	$ 0.03	$ 0.08
Historical net income per share - Diluted
Net income	$ 2,290	$ 5,867
Weighted average number of common shares outstanding	71,592,089	70,916,828
Effect of dilutive stock options	2,870,789	4,001,490
Weighted average number of common shares outstanding	74,462,878	74,918,318
Diluted net income per common share	$ 0.03	$ 0.08

Note 8 - Net Income Per Share42

Note 8 - Net Income Per Share - Textual (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,419,359	1,584,504

Note 9 - Product Lines, Concent

Note 9 - Product Lines, Concentration of Credit Risk and Significant Customers - Textual (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Concentration Risk, Percentage	100.00%	100.00%
Pharmaceutical Wholesalers [Member] | Product Shipments [Member]
Concentration Risk, Number of Customers	3	4
Pharmaceutical Wholesalers [Member] | Product Shipments [Member] | Customer One [Member]
Concentration Risk, Percentage	21.00%	28.00%
Pharmaceutical Wholesalers [Member] | Product Shipments [Member] | Customer Two [Member]
Concentration Risk, Percentage	19.00%	23.00%
Pharmaceutical Wholesalers [Member] | Product Shipments [Member] | Customer Three [Member]
Concentration Risk, Percentage	16.00%	19.00%
Pharmaceutical Wholesalers [Member] | Product Shipments [Member] | Customer Four [Member]
Concentration Risk, Percentage		18.00%
Pharmaceutical Wholesalers [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers	2		4
Pharmaceutical Wholesalers [Member] | Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage	25.00%		20.00%
Pharmaceutical Wholesalers [Member] | Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk, Percentage	25.00%		19.00%
Pharmaceutical Wholesalers [Member] | Accounts Receivable [Member] | Customer Three [Member]
Concentration Risk, Percentage			17.00%
Pharmaceutical Wholesalers [Member] | Accounts Receivable [Member] | Customer Four [Member]
Concentration Risk, Percentage			14.00%
Specialty Pharmaceutical Retailers [Member] | Product Shipments [Member]
Concentration Risk, Percentage	27.00%
Concentration Risk, Number of Customers	1
Subsys [Member]
Number of Product Lines	1

Note 9 - Product Lines, Conce44

Note 9 - Product Lines, Concentration of Credit Risk and Significant Customers - Summary of Net Revenue by Product Line and Percentages (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues	$ 60,421	$ 67,692
Subsys [Member]
Revenues	$ 60,421	67,462
Dronabinol Sg Capsule [Member]
Revenues		$ 230

Note 9 - Product Lines, Conce45

Note 9 - Product Lines, Concentration of Credit Risk and Significant Customers - Percentage of Revenue by Route to Market (Detail)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Concentration Risk, Percentage	100.00%	100.00%
Sales Revenue, Product Line [Member] | Pharmaceutical Wholesalers [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	73.00%	100.00%
Sales Revenue, Product Line [Member] | Specialty Pharmaceutical Retailers [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	27.00%	0.00%